Engineered heparin oligosaccharide keeps anticoagulant power while sidestepping the platelet factor 4 trigger of HIT
- A uniform, chemoenzymatically built heparin oligosaccharide carries extra sulfation that stiffens its shape and weakens platelet factor 4 binding, while the antithrombin-binding region stays intact.
- In mice, antithrombotic efficacy matched enoxaparin in venous settings and exceeded it in arterial ones, and protamine reversed the compound more readily.
- HIT-mimicking antibodies barely activated human platelets, and liver toxicity and immunogenicity were low.
💡 Points Based on the abstract
Mouse PF4 biology is a weak stand-in here: HIT hinges on human PF4/heparin complexes and FcγRIIa-driven platelet activation, so I would not lean on the mouse efficacy. Beating enoxaparin in arterial models is notable, but I want anti-Xa and aPTT exposure matching and bleeding time at equipotent doses. Next: ex vivo HIT sera from real patients, plus primate PK and half-life.